Common supplement tested as lifeline for COVID's sickest patients
NCT ID NCT07374991
Summary
This study tested whether adding the drug N-acetylcysteine (NAC) to standard care could help control severe lung inflammation in COVID-19 patients in the ICU. Researchers gave NAC or a placebo to 59 critically ill patients and tracked their blood markers and recovery. The goal was to see if NAC could reduce harmful inflammation and improve outcomes like survival and time in the hospital.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19-ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gaziantep üniversity
Gaziantep, 27, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.